Old Web
English
Sign In
Acemap
>
authorDetail
>
Gert van Deijk
Gert van Deijk
Metastatic breast cancer
Medicine
Docetaxel
Breast cancer
Oncology
3
Papers
82
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
2011
Clinical Breast Cancer
Paul Hamberg
Monique M.E.M. Bos
Hans J Braun
Jacqueline Stouthard
Gert van Deijk
Frans Erdkamp
Iris N. van der Stelt-Frissen
M. Bontenbal
Geert-Jan Creemers
J.E.A. Portielje
J.F.M. Pruijt
Olaf Loosveld
Willem M. Smit
Erik W. Muller
P.I.M. Schmitz
Caroline Seynaeve
J.G.M. Klijn
Show All
Source
Cite
Save
Citations (55)
Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel
2011
European Journal of Cancer
Carolien P. Schröder
Linda de Munck
Anneke M. Westermann
Willem M. Smit
Geert-Jan Creemers
Hiltje de Graaf
Jacqueline M. Stouthard
Gert van Deijk
Zoran Erjavec
Aart van Bochove
Willemijn Vader
Pax H. B. Willemse
Show All
Source
Cite
Save
Citations (24)
A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer
2007
Breast Cancer Research and Treatment
Phb Willemse
Linda de Munck
G-J. Creemers
H Graaf
Willem M. Smit
Zoran Erjavec
Jacqueline Stouthard
Gert van Deijk
Aart van Bochove
W. Vader
A. M. Westermonn
Show All
Source
Cite
Save
Citations (3)
1